Efficacy and safety of multiple doses of tapentadol oral solution in the treatment of moderate to severe acute pain in children aged 2 to <18 years – a randomized, double-blind, placebo-controlled trial

References

• Eerdekens M, Beuter C, Lefeber C, van den Anker J. The challenge of developing pain medications for children: therapeutic needs and future perspectives. J Pain Res. 2019; 12:1649–1664.31213880
   PubMed Web of Science ®Google Scholar
• Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use, OJ L 378, 27.12.2006. Available from: https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2006_1901/reg_2006_1901_en.pdf Accessed 928, 2018.
   Google Scholar
• Food and Drug Administration. Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients–FDA. Final rule. Fed Regist. 1998;63(231):66631–66672.10338880
   PubMedGoogle Scholar
• American Academy of Pediatrics, American Pain Society. The assessment and management of acute pain in infants, children, and adolescents. Pediatrics. 2001;108(3):793–797. doi:10.1542/peds.108.3.79311533354
   PubMed Web of Science ®Google Scholar
• Association of Paediatric Anaesthetists of Great Britain and Ireland. Good practice in postoperative and procedural pain management, 2nd edition. Paediatr Anaesth. 2012;22(suppl1):1–79. doi:10.1111/j.1460-9592.2012.03838.x
   Google Scholar
• Tzschentke TM, De Vry J, Terlinden R, et al. Tapentadol hydrochloride. Analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitor. Drugs Future. 2006;31:1053–1061.
   Web of Science ®Google Scholar
• Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr Med Res Opin. 2009;25:1095–1104. doi:10.1185/0300799090281697019301989
   PubMed Web of Science ®Google Scholar
• Hartrick C, Van Hove I, Stegmann JU, Oh C, Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCL immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009;31:260–271. doi:10.1016/j.clinthera.2009.02.00919302899
   PubMed Web of Science ®Google Scholar
• Daniels SE, Upmalis D, Okamoto A, Lange C, Haeussler J. A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr Med Res Opin. 2009;25:765–776. doi:10.1185/0300799090272818319203298
   PubMed Web of Science ®Google Scholar
• Daniels S, Casson E, Stegmann JU, et al. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr Med Res Opin. 2009;25:1551–1561. doi:10.1185/0300799090295282519445652
   PubMed Web of Science ®Google Scholar
• Vorsanger GJ, Klopfer AM, Xiang J, Benson CJ, Moskovitz BL, Rosenthal NR. Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: a randomized, phase IIIb study. J Opioid Manage. 2013;9:281–290. doi:10.5055/jom.2013.0170
   Google Scholar
• Biondi D, Xiang J, Benson C, Etropolski M, Moskovitz B, Rauschkolb C. Tapentadol immediate release versus oxycodone immediate release for treatment of acute low back pain. Pain Physician. 2013;16:E237–E246.23703422
   PubMed Web of Science ®Google Scholar
• Vorsanger GJ, Farrell J, Xiang J, Chow W, Moskovitz BL, Rosenthal NR. Tapentadol, oxycodone or placebo for acute pain of vertebral compression fractures: a randomized phase IIIb study. Pain Manage. 2013;3:109–118. doi:10.2217/pmt.13.5
   Google Scholar
• Viscusi E, Allard R, Sohns M, Eerdekens M. Tapentadol immediate release for moderate to severe acute post-surgery pain. J Opioid Manage. 2019;15:51–67. doi:10.5055/jom.2019.0486
   Google Scholar
• Baron R, Eberhart L, Kern KU, et al. Tapentadol prolonged release for chronic pain: a review of clinical trials and 5 years of routine clinical practice data. Pain Pract. 2017;17:678–700. doi:10.1111/papr.1251527611642
   PubMed Web of Science ®Google Scholar
• Raffa RB, Elling C, Tzschentke TM. Does ‘strong analgesic’ equal ‘strong opioid’? Tapentadol and the concept of ‘µ-load’. Adv Ther. 2018;35:1471–1484. doi:10.1007/s12325-018-0778-x30206823
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium. Palexia 50 mg film-coated tablets. Available from: https://www.medicines.org.uk/emc/medicine/28375 Accessed 1015, 2018.
   Google Scholar
• Smit JW, Oh C, Rengelshausen J, et al. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies. Pharmacotherapy. 2010;30(1):25–34. doi:10.1592/phco.30.1.2520030470
   PubMed Web of Science ®Google Scholar
• Finkel J, Goldberg J, Rosenburg R, et al. First evaluation of tapentadol oral solution for the treatment of moderate to severe acute pain in children aged 6 to <18. J Pain Res. 2019;12:1925–1936. doi:10.2147/JPR.S19734831303784
   PubMed Web of Science ®Google Scholar
• Muse D, Tarau E, Lefeber C, et al. Pharmacokinetics, safety, and efficacy of tapentadol oral solution for treating moderate to severe pain in pediatric patients. J Pain Res. 2019;12:1777–1790.31213888
   PubMed Web of Science ®Google Scholar
• Watson E, Khandelwal A, Freijer J, van den Anker J, Lefeber C, Eerdekens M. Population pharmacokinetic modeling to facilitate dose selection of tapentadol in the pediatric population. J Pain Res. 2019;12:2835–2850.31686902
   PubMed Web of Science ®Google Scholar
• Berde CB, Walco GA, Krane EJ, et al. Pediatric analgesic clinical trial designs, measures, and extrapolation: report of an FDA scientific workshop. Pediatrics. 2012;129(2):354–364. doi:10.1542/peds.2010-359122250028
   PubMed Web of Science ®Google Scholar
• Walco GA, Kopecky EA, Weisman SJ, et al. Clinical trial designs and models for analgesic medications for acute pain in neonates, infants, toddlers, children, and adolescents: ACTTION recommendations. Pain. 2018;159:193–205. doi:10.1097/j.pain.000000000000110429140927
   PubMed Web of Science ®Google Scholar
• Kossowsky J, Donado C, Berde CB. Immediate rescue designs in pediatric analgesic trials: a systematic review and meta analysis. Anesthesiology. 2015;122(1):150–171. doi:10.1097/ALN.000000000000044525222831
   PubMed Web of Science ®Google Scholar
• Merkel SI, Voepel-Lewis T, Shayevitz JR, Malviya S. The FLACC: a behavioral scale for scoring postoperative pain in young children. Pediatr Nurs. 1997;23:293–297.9220806
   PubMedGoogle Scholar
• Hicks CL, von Baeyer CL, Spafford PA, van Korlaar I, Goodenough B. The faces pain scale-revised: toward a common metric in pediatric pain measurement. Pain. 2001;93:173–183. doi:10.1016/s0304-3959(01)00314-111427329
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology. (DHEW Publication no. ADM 76-338). Washington, DC: US Government Printing Office; 1976. doi:10.1084/jem.143.4.741
   Google Scholar
• Guinard JX. Sensory and consumer testing with children. Trends Food Sci Technology. 2001;11(8):273–283. doi:10.1016/S0924-2244(01)00015-2
   Web of Science ®Google Scholar
• Posner K, Brent D, Lucas C, et al. Columbia-Suicide Severity Rating Scale (C-SSRS). Available from: http://cssrs.columbia.edu/wp-content/uploads/C-SSRS_Pediatric-SLC_11.14.16.pdf Accessed 1022, 2018.
   Google Scholar
• Rugytė D, Kokki H. Intravenous ketoprofen as an adjunct to patient-controlled analgesia morphine in adolescents with thoracic surgery: a placebo controlled double-blinded study. Eur J Pain. 2007;11:694–699. doi:10.1016/j.ejpain.2006.11.00117185016
   PubMed Web of Science ®Google Scholar
• Rusy LM, Hainsworth KR, Nelson TJ, et al. Gabapentin use in pediatric spinal fusion patients: a randomized, double-blind, controlled trial. Anesth Analg. 2010;110:1393–1398. doi:10.1213/ANE.0b013e3181d41dc220418301
   PubMed Web of Science ®Google Scholar
• Pica N, Bourgeois F. Discontinuation and nonpublication of randomized clinical trials conducted in children. Pediatrics. 2016;138(3):e20160223. doi:10.1542/peds.2016-022327492817
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain. 2008;9(2):105–121. doi:10.1016/j.jpain.2007.09.00518055266
   PubMed Web of Science ®Google Scholar
• Dahan A, Aarts L, Smith TW. Incidence, reversal, and prevention of opioid-induced respiratory depression. Anesthesiology. 2010;112:226–238. doi:10.1097/ALN.0b013e3181c38c2520010421
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium. Palexia oral solution 20 mg/mL. Available from: https://www.medicines.org.uk/emc/product/5346/smpc Accessed 1119, 2018.
   Google Scholar